Corcept Therapeutics oncology chief sells 8,333 shares

The two sales were made under a Rule 10b5-1 plan adopted June 17, 2026, before Roberto Wandenkolk Vieira became an officer.

Available on EDGAR 11/04/2026 - 07:21 PM EST Accepted by SEC EDGAR 11/04/2026 - 07:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Roberto Wandenkolk Vieira, Corcept Therapeutics Inc.'s President, Oncology, exercised options covering 8,333 common shares on November 2, 2026, at $21.63 per share. He also sold 8,333 shares in two transactions: 6,657 at a weighted average of $80.7326 per share and 1,676 at $81.5226 per share. Both sales were made under a Rule 10b5-1 plan adopted June 17, 2026, before he became an officer. The reported option position after exercise was 125,001 shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 8,333 shares ($494K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Vieira Roberto Wandenkolk

Role President, Oncology

Sold 8,333 shs ($674K)

Approx. gross sale proceeds $674K

Approx. exercise cost $180K

Approx. pre-tax spread $494K

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) F5	8,333	$0.00	$0.00
Exercise	Common Stock F1	8,333	$21.63	$180K
Sale	Common Stock F2, F3, F1	6,657	$80.7326	$537K
Sale	Common Stock F2, F4, F1	1,676	$81.5226	$137K

Holdings After Transaction: Stock option (right to buy) — 125,001 contracts (Direct); Common Stock — 3,946 shares (Direct)

Footnotes (5)

1. F1. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.15 to $81.12 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.17 to $82.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. F5. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.

Key Figures

Shares acquired through option exercise: 8,333 shares Option exercise price: $21.63 per share First sale: 6,657 shares at a weighted average $80.7326 per share +3 more

6 metrics

Shares acquired through option exercise 8,333 shares November 2, 2026

Option exercise price $21.63 per share Options exercised November 2, 2026

First sale 6,657 shares at a weighted average $80.7326 per share November 2, 2026

Second sale 1,676 shares at a weighted average $81.5226 per share November 2, 2026

Option position after exercise 125,001 shares Reported after the November 2, 2026 exercise

Option expiration February 1, 2034 Stock option

Key Terms

Rule 10b5-1 plan, weighted average sale price, restricted stock awards

3 terms

Rule 10b5-1 plan regulatory

"made pursuant to a 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"Represents the weighted average sale price"

restricted stock awards financial

"shares underlying unvested restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CORT shares did Roberto Wandenkolk Vieira sell and at what prices?

Roberto Wandenkolk Vieira sold 8,333 CORT shares on November 2, 2026: 6,657 at a weighted average $80.7326 per share and 1,676 at a weighted average $81.5226 per share. Both sales were made under a Rule 10b5-1 plan adopted June 17, 2026, before he was appointed an officer.

How many CORT options did Roberto Wandenkolk Vieira exercise?

He exercised options covering 8,333 common shares on November 2, 2026, at $21.63 per share. The reported option position after the exercise was 125,001 shares, and the option expires February 1, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vieira Roberto Wandenkolk

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Oncology

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		M		8,333	A	$21.63	12,279(1)	D
Common Stock	11/02/2026		S(2)		6,657	D	$80.7326(3)	5,622(1)	D
Common Stock	11/02/2026		S(2)		1,676	D	$81.5226(4)	3,946(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$21.63	11/02/2026		M			8,333	(5)	02/01/2034	Common Stock	8,333	$0.00	125,001	D

Explanation of Responses:

1. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.15 to $81.12 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.17 to $82.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Roberto Wandenkolk Vieira	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)